Business
Cognition Therapeutics Reports Financial Results for the Second Quarter 2025 and Highlights Progress Across Clinical Programs
- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting - - Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) - - Surpassed 50% enrollment in Phase 2 ‘START’ study of zervimesine in early Alzheimer’s disease - PURCHASE, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders
About this update from Cognition Therapeutics, Inc.
[{"type":"image","alt":"Cognition Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Cognition Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":250,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/3G97CJjBroOGRUYevL.t.A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTExODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/cc90d0cfc1ad93cdee05813266446f22","width":250,"height":70}},"lazy":false},{"type":"text","content":"- Discussed plans to support a pivotal Alzheimer’s disease program with FDA at end-of-phase 2 meeting -","length":103,"tagName":"p"},{"type":"text","content":"- Initiated expanded access program (EAP) for people with dementia with Lewy bodies (DLB) -","length":91,"tagName":"p"},{"type":"text","content":"- Surpassed 50% enrollment in Phase 2 ‘START’ study of zervimesine in early Alzheimer’s disease - ","length":97,"tagName":"p"},{"type":"text","content":"PURCHASE, N.Y., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc. (the “Company” or “Cognition”) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders, today reported financial results for the second quarter ended June 30, 2025, and provided a business update.","length":316,"tagName":"p"},{"type":"text","content":"“The second quarter of 2025 has been very productive, with milestones from each of our clinical programs,” stated Lisa Ricciardi, Cognition’s president and CEO. “These accomplishments highlight the potential for zervimesine to slow the progression of age-related degenerative diseases such as Alzheimer’s disease, dementia with Lewy bodies (DLB) and dry age-related macular degeneration (dry AMD). The clinical findings from each program have been supplemented by the publication of proteomic analyses and in vitro studies that support the mechanism of action of zervimesine in these patient populations.”","length":605,"tagName":"p"},{"type":"text","content":"Business and Corporate Highlights","length":33,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Conducted productive EOP2 meeting with FDA to review results from the Phase 2 ‘SHINE’ study of zervimesine (CT1812) in Alzheimer’s disease;","length":139,"tagName":"p"}]},{"val":[{"type":"text","content":"Surpasse...